Arrayjet, a provider of inkjet liquid handling solutions, has announced that its ArrayPlex discovery platfrom has been selected by Immunome, Inc., a biotechnology company dedicated to developing targeted cancer therapies. Immunome selected the platform to expand its in-house high-throughput screening tools.
The proprietary multi-layer microarray platform is also available to Arrayjet’s screening in-house.
ArrayPlex was created by Arrayjet to meet the assay requirements of its customers for high-throughput screening services and tools. During Arrayjet’s seven year partnership with Immunome, Arrayjet performed screening services using the ArrayPlex platform.
The company says the platform underwent further optimisation, most recently to integrate internal assay controls and enhanced data normalisation.
Read more: 3D bioprinting developments signal ‘turning point’ for regenerative medicine
ArrayPlex is a patented spot-on-spot microarray platform that enables the rapid creation of multi-layered assays. This approach allows two libraries to be screened against each other for unique binding interactions, generating hits without prior knowledge of either ligand or target at high throughput. Arrayjet says it typically provides two-million data points per one 10-day cycle.
In addition to screening between antibody and lysate libraries, the platform is also compatible with a broad spectrum of other sample types, such as small molecule libraries, protein panels, nucleic acid libraries, detecting hits at an equal or higher sensitivity compared to ELISA.
“ArrayPlex is a major success story for ArrayJet, a culmination of years of hard work,” said Dr Iain McWilliam, Chief Executive Officer of Arrayjet. “Over the years, we have screened hundreds of thousands of antibodies against hundreds of cancer tissue lysates all the while while honing the assay. As a team, we are proud to see ArrayPlex incorporated into Immunome’s powerful in-house operations as one of its tools for advancing cancer therapeutic discovery, and we are excited about the platform also being available to our wider customer base.”
